Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration

Int J Biochem Cell Biol. 2012 Nov;44(11):1929-36. doi: 10.1016/j.biocel.2012.07.009. Epub 2012 Jul 17.

Abstract

Endothelial cells play a central role in inflammatory responses, mediating leukocyte and solute traffic from blood vessels into the tissue, and are therefore key targets for anti-inflammatory therapies. Phosphoinositide 3-kinases (PI3Ks) are important signal transducers in inflammation and cancer, however there are 8 different PI3K catalytic isoforms, several of which have been shown to play distinct roles in cellular responses. Isoform-selective inhibitors have recently been described, but their effects on endothelial cell responses have not been compared. Here we compare the effects of the pan-PI3K inhibitor wortmannin with that of four more isoform-selective inhibitors, PI-103, TGX-221, AS604850 and IC87114, on endothelial cells stimulated with the pro-inflammatory cytokine TNFα. We find that PI-103 and wortmannin are most effective at reducing both endothelial permeability and leukocyte transendothelial migration (TEM), which correlates with a decrease in both the activity of the tyrosine kinase Pyk2 and its association with VE-cadherin. PI-103-related compounds are therefore likely to be good candidates for treating chronic inflammatory responses involving TNFα.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Androstadienes / pharmacology
  • Antigens, CD / metabolism
  • Cadherins / metabolism
  • Capillary Permeability / drug effects*
  • Cell Membrane Permeability / drug effects*
  • Cell Shape / drug effects
  • Class Ia Phosphatidylinositol 3-Kinase / metabolism
  • Dioxoles / pharmacology
  • Endothelial Cells / cytology*
  • Endothelial Cells / drug effects
  • Endothelial Cells / enzymology
  • Focal Adhesion Kinase 2 / metabolism
  • Furans / pharmacology
  • Human Umbilical Vein Endothelial Cells / cytology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Leukocytes / cytology*
  • Leukocytes / drug effects
  • Leukocytes / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoinositide-3 Kinase Inhibitors*
  • Phosphorylation / drug effects
  • Protein Binding / drug effects
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Quinazolines / pharmacology
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / metabolism
  • Thiazolidinediones / pharmacology
  • Transendothelial and Transepithelial Migration / drug effects*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Wortmannin

Substances

  • 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione
  • Androstadienes
  • Antigens, CD
  • Cadherins
  • Dioxoles
  • Furans
  • IC 87114
  • PI103
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrimidines
  • Quinazolines
  • Thiazolidinediones
  • Tumor Necrosis Factor-alpha
  • cadherin 5
  • Class Ia Phosphatidylinositol 3-Kinase
  • Focal Adhesion Kinase 2
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Adenine
  • Wortmannin